| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 1,143,000 | - | ||
| General and administrative | 151,451,000 | - | ||
| Formation and operating costs | - | 374,857 | ||
| Total operating expenses | 152,594,000 | - | ||
| Loss from operations | -152,594,000 | -374,857 | ||
| Income on trust account | - | 18,080 | ||
| Interest expense | - | 28,345 | ||
| Net loss and comprehensive loss | -152,594,000 | -385,122 | ||
| Earnings per share, basic | -0.76 | - | ||
| Earnings per share, diluted | -0.76 | - | ||
| Weighted average number of shares outstanding, basic | 201,686,617 | - | ||
| Weighted average number of shares outstanding, diluted | 201,686,617 | - | ||
Semnur Pharmaceuticals, Inc. (DNQAF)
Semnur Pharmaceuticals, Inc. (DNQAF)